Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre P Zavascki

Showing results (51-60 of 66) with videos related to

Pageof 7
Sort By:
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2013
Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimensAna M Sandri, Cornelia B Landersdorfer, Jovan Jacob, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2026
Global Survey on the Management of Multidrug-resistant Gram-negative Bacilli: Divergence of Practice Between High-Income Countries and the Rest of the WorldAbi Manesh, Abdullah T Aslan, Mithun Mohan George, et al.
The American Journal of Tropical Medicine and Hygiene|July 27, 2022
Evaluation of Clinical Course of Gamma (P.1) Variant of Concern versus Lineages in Hospitalized Patients with COVID-19 in a Reference Center in BrazilAlexandre P Zavascki, Tarsila Vieceli, Priscila Lamb Wink, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 23, 2021
Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patientsPatrick O Hanafin, Roger L Nation, Marc H Scheetz, et al.
Antimicrobial Agents and Chemotherapy|April 17, 2019
Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled TrialsYuanyuan Jiao, Bartolome Moya, Mong-Jen Chen, et al.
Infectious Diseases and Therapy|December 12, 2025
Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Causing Healthcare-Associated Bloodstream Infections in Brazil: Results from A Prospective Countrywide Multicenter StudyLaura C Antochevis, Letícia O Sudbrack, Robson S Leão, et al.
Pharmacotherapy|February 3, 2019
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)Brian T Tsuji, Jason M Pogue, Alexandre P Zavascki, et al.
Infectious Diseases and Therapy|December 15, 2023
A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial ProtocolBeatriz Arns, Jaqueline Driemeyer C Horvath, Gabriela Soares Rech, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 22, 2023
A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patientsPatrick O Hanafin, Andrea Kwa, Alexandre P Zavascki, et al.
Mbio|February 13, 2020
Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> and <i>Enterobacter cloacae</i>Tae Hwan Kim, Xun Tao, Bartolome Moya, et al.
Pageof 7

Showing results (51-60 of 66) with videos related to

Sort By:
Pageof 7
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 24, 2013
Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimensAna M Sandri, Cornelia B Landersdorfer, Jovan Jacob, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2026
Global Survey on the Management of Multidrug-resistant Gram-negative Bacilli: Divergence of Practice Between High-Income Countries and the Rest of the WorldAbi Manesh, Abdullah T Aslan, Mithun Mohan George, et al.
The American Journal of Tropical Medicine and Hygiene|July 27, 2022
Evaluation of Clinical Course of Gamma (P.1) Variant of Concern versus Lineages in Hospitalized Patients with COVID-19 in a Reference Center in BrazilAlexandre P Zavascki, Tarsila Vieceli, Priscila Lamb Wink, et al.
CPT: Pharmacometrics & Systems Pharmacology|November 23, 2021
Assessing the predictive performance of population pharmacokinetic models for intravenous polymyxin B in critically ill patientsPatrick O Hanafin, Roger L Nation, Marc H Scheetz, et al.
Antimicrobial Agents and Chemotherapy|April 17, 2019
Comparable Efficacy and Better Safety of Double β-Lactam Combination Therapy versus β‑Lactam plus Aminoglycoside in Gram-Negative Bacteria in Randomized, Controlled TrialsYuanyuan Jiao, Bartolome Moya, Mong-Jen Chen, et al.
Infectious Diseases and Therapy|December 12, 2025
Molecular Epidemiology of Methicillin-Resistant Staphylococcus aureus Causing Healthcare-Associated Bloodstream Infections in Brazil: Results from A Prospective Countrywide Multicenter StudyLaura C Antochevis, Letícia O Sudbrack, Robson S Leão, et al.
Pharmacotherapy|February 3, 2019
International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP)Brian T Tsuji, Jason M Pogue, Alexandre P Zavascki, et al.
Infectious Diseases and Therapy|December 15, 2023
A Randomized, Open-Label, Non-inferiority Clinical Trial Assessing 7 Versus 14 Days of Antimicrobial Therapy for Severe Multidrug-Resistant Gram-Negative Bacterial Infections: The OPTIMISE Trial ProtocolBeatriz Arns, Jaqueline Driemeyer C Horvath, Gabriela Soares Rech, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|May 22, 2023
A population pharmacokinetic model of polymyxin B based on prospective clinical data to inform dosing in hospitalized patientsPatrick O Hanafin, Andrea Kwa, Alexandre P Zavascki, et al.
Mbio|February 13, 2020
Novel Cassette Assay To Quantify the Outer Membrane Permeability of Five β-Lactams Simultaneously in Carbapenem-Resistant <i>Klebsiella pneumoniae</i> and <i>Enterobacter cloacae</i>Tae Hwan Kim, Xun Tao, Bartolome Moya, et al.
Pageof 7